CNBC November 8, 2023
Key Points
– The Food and Drug Administration approved Eli Lilly’s tirzepatide drug for weight loss, paving the way for even wider use of the blockbuster medication.
– The active ingredient in the drug, tirzepatide, has already been approved for the treatment of Type 2 diabetes under the name Mounjaro since May 2022.
– But the FDA’s new approval means adults who have obesity or are overweight with at least one weight-related condition can use the drug, which will be marketed as Zepbound, for chronic weight management.
The Food and Drug Administration on Wednesday approved Eli Lilly‘s blockbuster drug tirzepatide for weight loss, paving the way for even wider use of the treatment in the U.S.
The active ingredient...
Today's Sponsors
Today's Sponsor